R&D channel feed

Dai­ichi ditch­es Nek­tar fol­low­ing can­cer drug flop

8 years ago

Sanofi faces a make-or-break year, say­ing it’s ready to put a 3-prong R&D strat­e­gy to a piv­otal test

8 years ago

Te­va sharp­ens ax, preps bru­tal cuts in R&D and across the group in face of crush­ing debt

8 years ago
Pharma

Re­gen­eron, Sanofi are ready to de­but the 6th PD-1/L1. Is it still pos­si­ble to stand out from the grow­ing crowd?

8 years ago

Aduro buries an­oth­er can­cer vac­cine af­ter CRS-207 joins the line­up of clin­i­cal dis­as­ters

8 years ago

#ASH17: Ab­b­Vie, Roche boast stel­lar PhI­II leukemia da­ta for a “break­through” com­bo with block­buster am­bi­tions

8 years ago

GSK of­fers en­cour­ag­ing da­ta on BC­MA-tar­get­ing armed an­ti­body, set­ting stage for a re­turn to late-stage can­cer stud­ies

8 years ago

#ASH17: Spark trig­gers a back­lash as ear­ly he­mo­phil­ia A gene ther­a­py da­ta looks shaky

8 years ago
Cell/Gene Tx

#ASH17: Sy­ros evis­cer­at­ed by in­vestor back­lash as lead drug flails bad­ly in PhII

8 years ago

Can GSK’s new R&D strat­e­gy re­sus­ci­tate the worst per­former in Big Phar­ma?

8 years ago
Bioregnum
Opinion

#ASH17: Ve­rastem's Ab­b­Vie castoff is head­ed for the FDA — even af­ter miss­ing over­all sur­vival goal

8 years ago

#ASH17: Blue­print el­bows its way to cen­ter ring with ear­ly da­ta and a plan to seek quick FDA OK

8 years ago

#ASH17: How does No­var­tis’ Kym­ri­ah DL­B­CL da­ta stack up head­ing straight to a CAR-T show­down with Gilead?

8 years ago

#ASH17: The BC­MA-tar­get­ed CAR-T bb2121 from blue­bird and Cel­gene takes a star turn in the spot­light

8 years ago

#ASH17: Roche un­veils stel­lar PhII DL­B­CL da­ta for one of its top hema­tol­ogy drugs in the pipeline

8 years ago

#ASH17: Seat­tle Ge­net­ics CEO Clay Sie­gall has an an­swer for the skep­tics doubt­ing Ad­cetris da­ta for Hodgkin lym­phoma

8 years ago

In a show­down with As­traZeneca, Pfiz­er posts sol­id — and very fa­mil­iar — PhI­II breast can­cer da­ta for ta­la­zoparib

8 years ago

Sage trig­gers an­oth­er burst of in­vestor en­thu­si­asm as oral de­pres­sion drug scores in PhII

8 years ago

Spark, Pfiz­er pass an­oth­er mile­stone with im­pres­sive re­sults treat­ing he­mo­phil­ia B

8 years ago

There are 2,004 can­cer im­munother­a­pies crowd­ing in­to the pipeline. Now what?

8 years ago

Look­ing for a come-from-be­hind win, Roche touts its piv­otal suc­cess for Tecen­triq com­bo in front-line lung can­cer

8 years ago

More ef­fi­cient rare pe­di­atric drug de­vel­op­ment: FDA drafts guid­ance

8 years ago

Juno inks deals with Eli Lil­ly, the Hutch as it looks to leapfrog lead­ers on BC­MA

8 years ago
Pharma

Madri­gal's stock soars on promis­ing PhII da­ta in NASH, but ques­tions linger

8 years ago
First page Previous page 286287288289290291292 Next page Last page
A service from the Financial Times